Bank of Montreal Can Has $5.16 Million Stake in Masimo Co. (MASI)

Bank of Montreal Can decreased its position in Masimo Co. (NASDAQ:MASI) by 47.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,316 shares of the medical equipment provider’s stock after selling 34,128 shares during the period. Bank of Montreal Can owned 0.07% of Masimo worth $5,160,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc grew its stake in shares of Masimo by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 4,147,708 shares of the medical equipment provider’s stock valued at $516,556,000 after buying an additional 109,065 shares during the period. FMR LLC boosted its position in shares of Masimo by 17.8% during the 4th quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock worth $417,622,000 after purchasing an additional 587,587 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd boosted its position in shares of Masimo by 12.6% during the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 779,500 shares of the medical equipment provider’s stock worth $83,694,000 after purchasing an additional 87,476 shares during the period. Victory Capital Management Inc. boosted its position in shares of Masimo by 13.3% during the 4th quarter. Victory Capital Management Inc. now owns 726,329 shares of the medical equipment provider’s stock worth $77,986,000 after purchasing an additional 85,255 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Masimo by 14.6% during the 4th quarter. Geode Capital Management LLC now owns 547,027 shares of the medical equipment provider’s stock worth $58,734,000 after purchasing an additional 69,627 shares during the period. 83.16% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on the stock. UBS Group increased their price objective on shares of Masimo from $147.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $158.00 price objective (up previously from $155.00) on shares of Masimo in a research report on Tuesday, May 7th. Piper Jaffray Companies increased their price objective on shares of Masimo from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $153.00 price objective for the company in a research report on Wednesday. Finally, BTIG Research cut shares of Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price objective for the company. in a research report on Tuesday, April 16th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $149.75.

In other Masimo news, CAO Ramshorst David J. Van sold 1,845 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $140.00, for a total transaction of $258,300.00. Following the sale, the chief accounting officer now directly owns 1,695 shares in the company, valued at approximately $237,300. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jon Coleman sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $140.00, for a total transaction of $280,000.00. Following the sale, the insider now owns 13,201 shares in the company, valued at $1,848,140. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,722 shares of company stock worth $4,582,310. 11.50% of the stock is owned by company insiders.

NASDAQ:MASI opened at $140.03 on Friday. The company has a market cap of $7.48 billion, a P/E ratio of 46.21, a P/E/G ratio of 2.80 and a beta of 1.12. Masimo Co. has a fifty-two week low of $95.53 and a fifty-two week high of $143.10.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.04. The firm had revenue of $231.70 million during the quarter, compared to analysts’ expectations of $223.67 million. Masimo had a net margin of 22.49% and a return on equity of 18.61%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company posted $0.75 EPS. As a group, analysts expect that Masimo Co. will post 3.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Bank of Montreal Can Has $5.16 Million Stake in Masimo Co. (MASI)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2019/05/12/bank-of-montreal-can-has-5-16-million-stake-in-masimo-co-masi.html.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Read More: What are economic reports?

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply